Back to JournalSector and Regulatory Diligence

Sector Licences and Regulatory Diligence Before an Angel Investment

Rupeia Research Desk4 min readAngel Investing

The decision this article answers

One regulatory mistake can defeat a promising angel investment. The correct question is not whether a startup is 'compliant' in the abstract, but which activities it performs, under which permissions and which future product plans create new obligations. A company may be allowed to write software without being allowed to offer regulated lending, sell a clinical device or conduct a particular space activity. Prominent customers and accelerator awards do not establish legal permission. Investors should understand the applicable perimeter before signing or paying.

How the structure actually works

Map the business step by step: marketing, data collection, production, customer onboarding, payments, delivery, exports, after-sales service and secondary uses of data. For each step, identify the contracting entity, geography, regulator and approval or filing claimed. Request copies of actual licences, registrations, no-objection letters and advice on exemptions. For Indian medical devices, regulatory pathways may involve CDSCO; private space activities may fall within IN-SPACe authorisation; financial services can engage RBI or SEBI requirements. Classification must be confirmed for the actual product and date.

Worked example and practical comparison

Consider a startup selling a cloud system to hospitals today and planning to add a diagnostic recommendation tomorrow. The first product may be an administrative tool, while the second may trigger different clinical and regulatory analysis. A deck showing future diagnostic revenue should therefore include the costs, evidence and permissions required to launch it. As another example, a lending marketplace may earn lawful software fees while also planning to take credit risk in a way that changes its regulatory treatment. The investment valuation should not give equal certainty to today's permitted activity and tomorrow's unapproved business.

Where the investment case can fail

Diligence should test the regulatory history and not only current certificates. Ask about past notices, inspections, product recalls, customer complaints, tax disputes and pending applications. A licence held by a partner is not automatically the startup's licence; read the agreement defining permitted functions and liabilities. Some businesses depend on a regulator accepting an interpretation that has not been formally tested. That uncertainty belongs in the risk discussion and financing plan rather than being hidden under a generic legal opinion.

What investors frequently overlook

The costs of compliance can reshape unit economics. Testing, quality systems, audits, security controls, qualified staff and reporting may be necessary before expansion. If a product will enter multiple jurisdictions, permissions may differ materially. Investors should ask whether capital raised is enough to achieve the relevant legal milestone and whether work must stop if approval is delayed. Legal diligence cannot make regulation certain; it can identify the decisions that would be affected by a change.

A decision rule before investing

A proportionate solution is a current regulatory map, copies of key approvals, a written unresolved-issues list and sector counsel's assessment of material exposures. Make any essential permission a closing condition or a clearly funded post-investment milestone. Avoid rewarding optimistic revenue forecasts that depend on acting before a legal approval. If the founders cannot articulate which legal rules govern their core revenue stream, the deal is not yet ready for a reasoned valuation.

Additional decision test: evidence and price discipline

A regulatory map should distinguish the product currently sold from products described in projections. List every required licence or operating condition, the entity holding it, the responsible employee, expiry date and possible consequence of a suspension. A general startup recognition certificate does not grant permission for specialised medical, financial or space operations. For partner-dependent models, check whether the partner agreement authorises every activity the startup performs and who handles breaches or complaints. Regulatory change should be modelled as a business risk: if approval takes six months longer, what must be cut or financed? The objective is not to eliminate uncertainty with one legal opinion but to price the cost and consequence of remaining unresolved requirements. The investment is incomplete when a core revenue activity has no credible lawful route to market.

Documents and questions to verify

Use the following four questions when interviewing the manager, founders or transaction counsel. For every answer, record a source document or independent confirmation, the document date and any unresolved exceptions. A verbal assurance should remain an open item until the underlying evidence is reviewed.

Map each revenue activity and geography to its regulator and permission.

Inspect actual licences, restrictions and expiry or renewal conditions.

Review past regulatory notices, recalls and unresolved legal advice.

Budget future compliance milestones and delays in the financing plan.

Red flags that justify pausing the decision

The company cites a partner licence as its own without checking scope.

A future regulated product is forecast to earn revenue before approvals.

Material legal notices or restrictions are omitted from diligence disclosures.

A warning sign is not automatic proof of wrongdoing. It is a reason to ask for evidence, model the downside more conservatively or decline the deal when a material issue cannot be resolved.

Sources and publication notes

Verified internal: Rupeia Journal, topic index · Checked 4 Nov 2026

Verified internal: How to Read an AIF PPM Before Investing · Checked 4 Nov 2026

External source: CDSCO Medical Device and Diagnostics regulatory overview (Checked 4 Nov 2026) · Open source

External source: IN-SPACe authorisation norms for space activities (2024 guidance, consulted 4 Nov 2026) · Open source

External source: Startup India: DPIIT recognition and tax exemption (Live guidance checked 4 Nov 2026) · Open source

External source: SEBI AIF Regulations, 2012 (amended to 15 October 2026) (15 Oct 2026) · Open source

Verification date: 4 November 2026. Regulatory rules, taxation and transaction documents require current case-specific review. Worked examples are educational and are not forecasts of actual investments.

Related questions

Does a DPIIT startup recognition substitute for sector licences?

No. Recognition does not replace product- or activity-specific authorisations.

Can counsel guarantee that rules will not change?

No. Counsel can analyse current compliance and identify material uncertainty.

Should an angel close before a key licence arrives?

Only after assessing legality, conditions, funding consequences and appropriate protections.

Need personalized advice?

Schedule a conversation about your private market allocation goals.

Request an advisory call